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Abstract
BACKGROUND: Because Alzheimer’s disease (AD) is 
characterized by a gradual decline, it can be difficult to identify 
distinct clinical milestones that signal disease advancement. 
Adapting a functional scale may be a useful way of staging 
disease progression that is more informative for healthcare 
systems. 
OBJECTIVES: To adapt functional scale scores into discrete 
levels of dependence as a way of staging disease progression 
that is more informative to care providers and stakeholders who 
rely on the functional impact of diseases to determine access to 
supportive services and interventions. 
DESIGN: Analysis of data from the GERAS study. 
SETTING: GERAS is an 18-month prospective, multicenter, 
naturalistic, observational cohort study reflecting the routine 
care of patients with AD in France, Germany, and the United 
Kingdom. 
PARTICIPANTS: Data were from baseline results of 1497 
community-living patients, aged ≥55 years, diagnosed with 
probable AD and their caregivers. 
MEASUREMENTS: We used data from the Alzheimer’s 
Disease Cooperative Study Activities of Daily Living Inventory 
(ADCS-ADL) and mapped items onto established categories of 
functional dependence, validated using clinical and economic 
measures. Cognitive function, behavioral symptoms, caregiver 
burden, and cost were assessed. Based on stages of functional 
dependence described by the Dependence Scale, individual 
ADCS-ADL items were used to approximate 6 dependence 
levels. 
RESULTS: There was a significant relationship between 
assigned level of dependence derived from the ADCS-ADL 
score and cognitive severity category. As the assigned level of 
dependence increased, the associated clinical and economic 
indicators demonstrated a pattern of greater disease severity.
CONCLUSIONS: This mapping provides initial support for 
dependence levels as appropriate interim clinical milestones 
that characterize the functional deficits associated with AD.
Key words: Alzheimer’s disease, observational study, informal care, 
caregiver burden. 
Introduction 
A lzheimer’s disease (AD) is  a chronic, progressive illness characterized by a decline in memory and cognitive abilities, loss of 
capacity in activities of daily living (ADL), reduced 
global functioning, and behavioral and psychological 
symptoms. Because the disease is characterized by 
a gradual decline, it can be difficult to identify clear 
milestones that signal clinically meaningful disease 
advancement. Transforming functional scale scores 
into discrete levels of disability may be a useful way of 
staging disease progression that is more informative to 
a variety of care providers and stakeholders who rely on 
the functional impact of diseases to determine access to 
supportive services and interventions. Furthermore, most 
previous studies of disease advancement have focused 
on one facet such as cognition or functional ability. Many 
different functional scales are used in clinical trials and 
observational studies of patients with AD, so finding 
a common heuristic across different scales would be 
useful to facilitate comparisons and build common 
understandings.       
Zhu et al. (2009) (1) recognized that deficits associated 
with AD, including deficits in cognition, function, and 
behavior, could be assessed with a single scale. They used 
the Dependence Scale (DS) (2) to assess the overall impact 
of these impairments because increasing impairments 
would lead to greater dependence on others (e.g., 
caregivers) for required care and service needs. They 
found that patient dependence was associated with the 3 
clinical endpoints as well as measures of cost. Jones et al. 
(2014) (3) proposed that dependence could be a marker 
for following disease progression. They found the DS to 
be a useful tool for assessing patients with AD because 
it combines the impact of changes in cognition, function, 
and behavior. They also found significant associations 
between scores on the DS and cost, patient quality of life, 
and caregiver perceived burden. 
With the objective of finding a common heuristic 
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across different scales, we mapped the Alzheimer’s 
Disease Cooperative Study Activities of Daily Living 
Inventory (ADCS-ADL) items onto levels of dependence 
derived from the DS definitions. This mapping was 
validated using additional clinical and economic 
measures.  
Methods
Participants and Study Design
GERAS is an 18-month, prospective, multicenter, 
naturalistic, observational, cohort study reflecting the 
routine care of patients with AD in France, Germany, and 
the United Kingdom, with a further 18-month follow-
up period in France and Germany. The study design 
and methods have been described elsewhere (4). Briefly, 
investigators enrolled community-living patients, aged 
≥55 years, diagnosed with probable AD according to the 
National Institute of Neurological and Communicative 
Disorders, and Stroke and Alzheimer’s Disease and 
Related Disorders Association criteria (NINCDS-
ADRDA) (5), with a Mini-Mental State Examination 
(MMSE) (6) score of ≤26, who were evaluated within 
the normal course of care. A further inclusion criterion 
was that the patient’s primary caregiver (other than a 
healthcare professional) was willing to participate in the 
study. To be included in the study, the caregiver had to 
be responsible for the patient for at least 6 months of the 
year. Patients with other potential causes of dementia 
were excluded from the study. All patients (or their 
legal representatives) and caregivers provided written 
informed consent and the study was approved by ethical 
review boards in each country.
Patient and Caregiver Data
Baseline data were evaluated for 1497 patients and 
their caregivers. Functional ability was assessed using 
the Alzheimer’s Disease Cooperative Study Activities 
of Daily Living Inventory (ADCS-ADL), a caregiver-
reported measure of a patient’s dependence in basic 
and instrumental (complex) ADL. Cognitive function 
was tested using the MMSE. Behavioral symptoms were 
assessed using the 12-item Neuropsychiatric Inventory 
(NPI) (7). Direct and indirect resource use was assessed 
using the Research Utilization in Dementia Scale (RUD) 
(8). Country-specific costs were assigned to each unit of 
resource utilization from the RUD. Information regarding 
patient health status was collected from caregivers via a 
proxy version of the EuroQol-5 Dimension (EQ-5D) (9). 
Caregivers also completed the Zarit Burden Inventory 
(ZBI) (10), a measure of caregivers’ subjective burden 
related to caring for a loved one. 
For the analysis, patients were stratified according to 
disease severity at baseline using MMSE criteria: mild 
AD (MMSE 21–26 points), moderate AD (MMSE 15–20 
points), or moderately severe/severe AD (MMSE <15) 
(based in part on NICE Guidance 217) (11). 
Categorizing Dependence Levels
The DS includes a scheme to derive a dependence level 
based on responses to the individual items. Based on the 
DS items included in each of these dependence levels, 
a theoretical scheme was devised for defining stages of 
functional dependence (Table 1). The pattern of responses 
depicting type and degree of impairment on individual 
items from the ADCS-ADL were used to approximate 
the 6 dependence levels, ranging from no instrumental 
ADL or basic ADL impairment (Level 0) to impaired 
transfer or complete incontinence (Level 5). Mapping 
from the ADCS-ADL questionnaire to the functional 
levels is shown in Table 2. 
Confirmatory factor analysis of ADCS-ADL data 
was conducted in order to create subscales to aid in the 
construction of dependence levels (12). Baseline data 
suggested a 4-factor solution that included factors for 
BADLs, domestic/household activities, communication/
engagement with the environment, and outside activities 
(Figure 1).
Once categorizations were completed, the profile 
of patients in each category was determined using the 
following measures: MMSE, EQ-5D (proxy), NPI, ZBI, 
total caregiver time, total societal costs, and patient 
medical costs. Mean values and 95% confidence intervals 
were calculated for scales in each functional dependence 
category.
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Table 1. Theory-driven assigned levels of dependence
Level Types of Impairments Care Needs
0 No IADL/BADL impairment None
1 Some supervision needed on isolated IADLs Independent living with check-ins
2 Supervision on multiple IADLs or loss of at least 1 
Household Activity
Limited/informal home care services
3 Supervision on all types of IADLs or home-bound Extensive home care services w/ supervision OR As-
sisted living
4 Supervision on some BADLs Assisted living + nursing support
5 Impaired transfer OR complete incontinence Nursing home
Abbreviations: BADL, Basic Activities of Daily Living; IADL, Instrumental Activities of Daily Living
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Statistical Analysis
All patients and associated caregivers who provided 
informed consent and fulfilled the study entry criteria 
were included in the present analysis. 
Descriptive statistics (means and standard deviations 
[SDs] or frequencies) were used to summarize all 
variables and were based on non-missing observations. 
Comparisons between AD severity groups used 
Cochran–Mantel–Haenszel tests for categorical data, 
stratified by country; for continuous data, analysis of 
variance (ANOVA) was used with independent factors 
for MMSE severity and country. 
The relationship between dependence levels and 
cognitive severity was assessed using the Cochran–
Mantel–Haenszel test. Generalized linear models (GLM) 
were run to test for differences between ADL levels for 
all outcome measures. For caregiver time, total societal 
costs and patient medical costs a GLM was fitted with 
a gamma distribution and log-link function, all other 
outcomes used GLM’s with a normal distribution and an 
identity link function. 
All data were analyzed using SAS software, version 9.2 
(SAS Institute, Cary, North Carolina, USA).
 
Results
Overall, 1532 patients and their primary caregivers 
were enrolled by 94 investigators. After excluding 35 
patients who did not fulfill the study entry criteria, a 
total of 1497 patients and caregivers were included in the 
analyses.
Descriptive Statistics
A summary of the patient characteristics is shown 
in Table 3. Full baseline patient characteristics were 
previously reported (4). The patients’ mean age was 77.6 
years and most patients were female (54.8). The mean 
MMSE score was 17.4.
The caregivers’ mean age was 67.3 years. Most of the 
caregivers were female (64.1%) and 65.9% were spouses 
of the patients. The mean ZBI score was 29.0. 
There was a significant relationship between the 
assigned level of dependence derived from the ADCS-
ADL score (0 to 5) and the cognitive severity category 
(mild/moderate/moderately severe or severe). Severity 
level increased with level of dependence (p<0.001; Figure 
2). 
As the assigned level of dependence increased (e.g., 
Level 1 to Level 5), the associated clinical indicators 
demonstrated a pattern of greater cognitive impairment 
(MMSE scores 23.2 to 10.0, p<0.001), higher levels of 
neuropsychiatric disturbance (NPI 3.7 to 27.6; p<0.001), 
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Table 2. Mapping from the ADCS-ADL questionnaire to the functional dependence levels 
Level Scoring Algorithm versus Care Needs
0 No impairments in ADCS-ADL
1 Level 2 on any 1 item from the following clusters: Household activities, Communication and Engagement, Outside 
Activities
2 Level 2 on items from at least 2 of the following clusters: Household activities, Communication and Engagement, 
Outside Activities, OR Level 1 on any item from the following clusters: Household activities, Communications and 
Engagement, Outside Activities,
OR Level 0 on any 1 item of Household activities
3 Level 2 for all items from the following clusters: Household activities, Communications and Engagement, Outside 
Activities, OR Level 0 on 1 item of Outside Activities, OR Level 2 for either item: Eating (Q1), Bathing (Q4)
4 Score <2 for item Dressing (Q6B), OR Level 1 or 0 or for any items: Grooming (Q5), Bathing (Q4), OR Level 2 for item 
Toileting (Q3), OR Level 0 for Eating (Q1)
5 Level 1 for Walking (Q2), OR Level 0 for Toileting (Q3)
Abbreviations: ADCS-ADL, Alzheimer’s Disease Cooperative Study-Activities of Daily Living; Q, question; Note: Q16B (Outdoor activity question) is not included); Q20 
(Communication question) only has a maximum level of 2, so the question is one point lower in the above settings.
Figure 1. ADL questions
greater caregiver burden (ZBI 15.0 to 35.2; p<0.001), 
lower quality of life (Patient EQ-5D 0.80 to 0.35; p<0.001; 
Caregiver EQ-5D 0.90 to 0.76; p<0.001), higher patient 
direct medical costs per month (€295 to €616; p<0.001) 
and total societal costs per month (€881 to €3725; 




This initial mapping of ADCS-ADL items onto 
levels of dependence derived from the DS definitions 
supports the feasibility of a shared metric for 
characterizing the functional deficits associated with 
AD. As the level of dependence increased, other clinical 
characteristics progressed in an expected manner as 
cognition worsened, quality of life decreased, and level of 
neuropsychiatric disturbance, caregiver time, and costs of 
care all increased. This suggests that levels of dependence 
are informative and describe intermediate steps along the 
continuum of AD. 
These results are consistent with previous studies 
that have used the DS itself. Lenderking et al. (2013) 
(13) measured the internal consistency, validity and 
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Table 3. Summary of patient and caregiver characteristics
Patient Severity
Characteristic Mild Moderate Moderately Severe/
Severe
p-Value All Patients
Number of patients 567 472 458 1497
Age, years (mean [SD]) 77.3 (6.97) 77.8 (7.95) 77.6 (8.17) 0.86 77.6 (7.66)
Gender (% female) 47.8 57.2 61.1 <0.001 54.8
MMSE (mean [SD]) 23.3 (1.6) 17.9 (1.7) 9.5 (4.3) NA 17.4 (6.3)
NPI (mean [SD]) 10.2 (10.8) 14.3 (12.6) 22.0 (19.4) <0.001 15.1 (15.3)
EQ-5D (mean [SD]) 0.71 (0.24) 0.64 (0.27) 0.51 (0.34) <0.001 0.63 (0.30)
Caregiver Characteristics
Number of caregivers 566 472 456 1494
Age, years (mean [SD]) 68.1 (11.6) 66.7 (11.7) 67.0 (12.9) 0.095 67.3 (12.0)
Gender (% female) 68.6 64.4 58.3 0.004 64.1
ZBI (mean [SD]) 24.7 (14.2) 29.4 (14.8) 34.1 (14.8) <0.001 29.0 (15.1)
Abbreviations: EQ-5D, EuroQol-5 Dimension; MMSE, Mini-Mental State Examination; NPI12, Neuropsychiatric Inventory-12; SD, standard deviation; ZBI, Zarit Burden 
Interview; For MMSE and EQ-5D, lower scores indicate greater severity. For NPI and ZBI, higher scores indicate greater severity
Table 4. Summary statistics by level of dependence














































1 35 (2%) 23.2 15.0 3.7 0.80 37.5 295 881
(22.2 – 24.2) (12.4 – 17.7) (2.7 – 4.8) (0.76 – 0.84) (19.5 - 55.6) (96 – 493) (559 – 1204)
2 443 (30%) 20.8 22.1 9.2 0.75 74.2 311 1091
(20.5 - 21.2) (20.9 - 23.3) (8.3 – 10.1) (0.73 – 0.77) (64.2 - 84.2) (227 – 395) (969 – 1212)
3 382 (26%) 18.3 30.6 14.5 0.67 177.5 353 1762
(17.8 - 18.8) (29.1 - 32.1) (13.2 - 15.9) (0.64 – 0.69) (159.7 - 195.3) (267 – 439) (1577 – 1946)
4 516 (34%) 14.8 33.8 19.0 0.53 276.0 412 2685
(14.2 - 15.3) (32.6 - 35.1) (17.6 - 20.4) (0.50 – 0.56) (259.1 – 292.8) (307 – 516) (2455 – 2915)
5 111 (7%) 10.1 35.2 27.6 0.35 349.4 616 3725
(8.6 – 11.5) (32.2 - 38.1) (23.3 – 32.0) (0.28 – 0.42) (310.4 – 388.4) (241 – 992) (3065 – 4386)
p value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: CI, confidence interval; EQ-5D, EuroQol-5 Dimension; MMSE, Mini-Mental State Examination; NPI12, Neuropsychiatric Inventory-12; ZBI, Zarit Burden 
Interview; *Based on small sample size.
responsiveness in patients with mild -to -moderately 
severe AD. They found the DS to be a reliable, valid, and 
interpretable measure in these patients. Zhu et al. (2008a) 
(14) estimated the effects of patients’ dependence and 
function on costs of care during the early stages of AD 
and found that the DS was associated with higher total 
cost. A one-point increase in the DS was associated with 
a $1,832 increase in total cost and a $1,690 increase in 
informal cost. A subsequent study by Zhu et al. (2008b) 
(15) found a one-point increase in the DS score was 
associated with a 4.1% increase in caregiving time. The 
current findings suggest that higher dependence levels 
may also be associated with increased cost.
Despite the even stratification of patients by their 
level of cognitive status (MMSE of mild, moderate, or 
moderately severe/severe) as specified in the GERAS 
study design, this same pattern of distribution was 
not noted for the levels of dependence. Relatively few 
patients were assigned to Levels 0, 1, or 5, reflecting 
the exclusion criteria for GERAS that would preclude 
enrollment of MCI patients or the most severe patients. 
The levels of interest for further exploration are therefore 
Levels 2, 3, and 4. Interestingly, Level 4 included 
approximately half of the GERAS participants. Although 
this may indicate a lack of granularity of this scaling 
scheme when patients reach a moderate level of cognitive 
impairment, it could also suggest that around this stage 
of disease, patients’ attempts to carry out basic ADL 
or household activities may not be as successful, and 
these attempts require more substantial supervision or 
assistance.
The application of this approach may be particularly 
useful in the characterization of patients in the mild stage 
of AD, where discrete clinical milestones are lacking. 
A majority of GERAS participants in the mild severity 
category, defined by baseline MMSE, were assigned to 
a dependence level marked by the need for supervision 
in completing multiple IADLs (Level 2). The magnitude 
of change reflected in the clinical and economic 
characteristics associated with the derived levels of 
dependence suggests that a transition between levels may 
represent clinically meaningful disease progression. For 
example, the burden associated with providing care for 
a patient with AD at a Level 3 was 38.5% greater than the 
level of burden experienced for caregivers of patients at 
Level 2. Likewise, caregiver time spent supervising and 
assisting with ADLs was 2.39 times greater in Level 3 
than Level 2, with significant changes in health utility and 
total societal costs also observed between these levels. 
Future efforts to evaluate the impact of treatments on 
interim milestones of dependence may provide important 
insights on the value of an intervention to a wide variety 
of stakeholders.
These functional categories may represent suitable 
clinical milestones for consideration as endpoints in 
trials of shorter duration that do not capture the entire 
spectrum of disease, though further research is needed 
to understand the timing of patients moving through 
these stages. Further analyses using longitudinal datasets 
might look at the number of patients shifting between 
levels of care over different time frames, with particular 
attention to patterns of shifts made over the course of 
18 months. It is also important to note that the study 
sample did not cover the entire spectrum of functional 
impairment. Very mild/asymptomatic and very severe 
patients were not part of the inclusion criteria. Assessing 
performance of these dependence levels across the full 
disease course is thus not possible.
These functional categories might also be applied 
to other commonly used functional scales using the 
theoretical model in Table 1. This would require evidence 
that the application of the theoretical model results 
in similar staging distributions even across different 
functional scales. This would have the advantage of 
creating a shared rubric for classifying dependence level 
across these different scales. 
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